Evidence map›Paper›PMID 27094739›Full record

Observational studyAlzheimer's research & therapy2016

CRTC1 gene is differentially methylated in the human hippocampus in Alzheimer's disease.

Maite Mendioroz, Naiara Celarain, Miren Altuna, Javier Sánchez-Ruiz de Gordoa, María Victoria Zelaya, Miren Roldán, Idoya Rubio, Rosa Larumbe, María Elena Erro, Iván Méndez and 1 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Alzheimer's research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. CRTC1 is a potential target to delay aging-induced cognitive deficit by protecting the integrity of the blood-brain barrier via inhibiting inflammation.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Maite MendiorozNeuroEpigenetics Laboratory, Navarrabiomed- IdiSNA (Navarra Institute for Health Research), c/ Irunlarrea, 3, Pamplona, Navarra, 31008, Spain. maitemendilab@gmail.com.
Naiara CelarainNeuroEpigenetics Laboratory, Navarrabiomed- IdiSNA (Navarra Institute for Health Research), c/ Irunlarrea, 3, Pamplona, Navarra, 31008, Spain.
Miren AltunaDepartment of Neurology, Complejo Hospitalario de Navarra- IdiSNA (Navarra Institute for Health Research), Pamplona, Navarra, 31008, Spain.
Javier Sánchez-Ruiz de GordoaNeuroEpigenetics Laboratory, Navarrabiomed- IdiSNA (Navarra Institute for Health Research), c/ Irunlarrea, 3, Pamplona, Navarra, 31008, Spain.
María Victoria ZelayaDepartment of Pathology, Complejo Hospitalario de Navarra- IdiSNA (Navarra Institute for Health Research), Pamplona, Navarra, 31008, Spain.
Miren RoldánNeuroEpigenetics Laboratory, Navarrabiomed- IdiSNA (Navarra Institute for Health Research), c/ Irunlarrea, 3, Pamplona, Navarra, 31008, Spain.
Idoya RubioDepartment of Neurology, Complejo Hospitalario de Navarra- IdiSNA (Navarra Institute for Health Research), Pamplona, Navarra, 31008, Spain.
Rosa LarumbeNeuroEpigenetics Laboratory, Navarrabiomed- IdiSNA (Navarra Institute for Health Research), c/ Irunlarrea, 3, Pamplona, Navarra, 31008, Spain.
María Elena ErroDepartment of Neurology, Complejo Hospitalario de Navarra- IdiSNA (Navarra Institute for Health Research), Pamplona, Navarra, 31008, Spain.
Iván MéndezNeuroEpigenetics Laboratory, Navarrabiomed- IdiSNA (Navarra Institute for Health Research), c/ Irunlarrea, 3, Pamplona, Navarra, 31008, Spain.
Carmen EchávarriNeuroEpigenetics Laboratory, Navarrabiomed- IdiSNA (Navarra Institute for Health Research), c/ Irunlarrea, 3, Pamplona, Navarra, 31008, Spain.
Complejo Hospitalario de Navarra · ESNavarrabiomed · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCRTC1 (CREB regulated transcription coactivator 1) gene plays a role in synaptic plasticity, learning and long-term memory formation in the hippocampus. Recently, CRTC1 has been shown to be downregulated in Alzheimer's disease (AD). Nevertheless, the mechanisms underlying CRTC1 dysregulation in AD remain unclear.

methodsTo understand better the epigenetic mechanisms regulating CRTC1 expression that may be altered in AD, we profiled DNA methylation at CpG site resolution by bisulfite cloning sequencing in two promoter regions (referred to as Prom1 and Prom2) of the CRTC1 gene in human hippocampus from controls and AD cases. Next, we correlated DNA methylation levels with AD-related pathology, i.e., β-amyloid and phosphorylated-tau (p-tau) burden and also measured CRTC1 mRNA levels by RT-qPCR.

resultsMethylation levels were lower in AD cases as compared to controls within both promoter regions (Prom1: 0.95% vs. 5%, p-value < 0.01 and Prom2: 2.80% vs. 17.80%, p-value < 0.001). Interestingly, CRTC1 methylation levels inversely correlated with AD-related neuropathological changes, particularly with p-tau deposition (rSpearman = -0.903, p < 0.001). Moreover, a 1.54-fold decrease in CRTC1 mRNA levels was observed in hippocampus of AD cases compared to controls (p < 0.05) supporting the notion that CRTC1 is downregulated in the AD hippocampus.

conclusionsDNA methylation levels within two distinct promoter regions of the CRTC1 gene were decreased in human hippocampus affected by AD compared with controls and methylation within Prom1 showed a strong inverse correlation with p-tau deposition. Further studies are guaranteed to elucidate the precise role that CRTC1 methylation plays in AD pathophysiology.

Indexed as

DNA MethylationAdultAgedAged, 80 and overAlzheimer DiseaseCase-Control StudiesEpigenesis, GeneticFemaleHippocampusHumansMaleMiddle AgedPromoter Regions, GeneticRNA, Messengertau ProteinsTranscription FactorsCRTC1 protein, humanMAPT protein, humanRNA, Messengertau ProteinsTranscription FactorsAlzheimer’s diseaseCRTC1DNA methylationEpigeneticsHippocampus

Identifiers

PMID27094739
PMCPMC4837517
OpenAlexW2341828758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.